Path ID: DB00922_MESH_D006333_2

Concepts
Identifier | Name | Type |
---|---|---|
MESH:C076731 | Levosimendan | Drug |
UniProt:Q14432 | cGMP-inhibited 3’,5’-cyclic phosphodiesterase A | Protein |
CHEBI:17489 | 3’,5’-cyclic AMP | ChemicalSubstance |
GO:0004679 | AMP-activated protein kinase activity | MolecularActivity |
GO:0005262 | Calcium channel activity | MolecularActivity |
GO:0070509 | Calcium ion import | BiologicalProcess |
GO:0060047 | Heart contraction | BiologicalProcess |
GO:0044557 | Relaxation of smooth muscle | BiologicalProcess |
GO:0042311 | Vasodilation | BiologicalProcess |
HP:0000822 | Hypertension | PhenotypicFeature |
MESH:D006333 | Congestive heart failure | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
Subject | Predicate | Object |
---|---|---|
Levosimendan | DECREASES ACTIVITY OF | Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A |
Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A | DECREASES ABUNDANCE OF | 3’,5’-Cyclic Amp |
3’,5’-Cyclic Amp | POSITIVELY REGULATES | Amp-Activated Protein Kinase Activity |
Amp-Activated Protein Kinase Activity | POSITIVELY REGULATES | Calcium Channel Activity |
Calcium Channel Activity | POSITIVELY REGULATES | Calcium Ion Import |
Calcium Ion Import | POSITIVELY REGULATES | Heart Contraction |
Heart Contraction | NEGATIVELY CORRELATED WITH | Congestive Heart Failure |
3’,5’-Cyclic Amp | POSITIVELY REGULATES | Relaxation Of Smooth Muscle |
Relaxation Of Smooth Muscle | POSITIVELY REGULATES | Vasodilation |
Vasodilation | NEGATIVELY CORRELATED WITH | Hypertension |
Hypertension | AFFECTS RISK FOR | Congestive Heart Failure |
Comment: Levosimendan has not been approved for use in the U.S. or Canada. It has been reported that levosimendan may act preferentially as a Ca2+ sensitizer at lower concentrations, whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.
Reference: